Vivos (OTCMKTS:RDGL) and Profound Medical (NASDAQ:PROF) Head to Head Survey

Vivos (OTCMKTS:RDGLGet Free Report) and Profound Medical (NASDAQ:PROFGet Free Report) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vivos and Profound Medical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivos 0 0 0 0 N/A
Profound Medical 0 1 1 1 3.00

Profound Medical has a consensus price target of $12.63, indicating a potential upside of 35.75%. Given Profound Medical’s higher possible upside, analysts plainly believe Profound Medical is more favorable than Vivos.


This table compares Vivos and Profound Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vivos -8,049.36% N/A -121.18%
Profound Medical -423.75% -55.78% -46.43%

Earnings and Valuation

This table compares Vivos and Profound Medical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vivos $40,000.00 578.08 -$2.47 million N/A N/A
Profound Medical $6.68 million 30.59 -$28.67 million ($1.37) -7.01

Vivos has higher earnings, but lower revenue than Profound Medical.

Institutional and Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. 18.5% of Vivos shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Vivos has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.


Profound Medical beats Vivos on 7 of the 12 factors compared between the two stocks.

About Vivos

(Get Free Report)

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Profound Medical

(Get Free Report)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.

Receive News & Ratings for Vivos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos and related companies with's FREE daily email newsletter.